WELCOME TO The PHARMACEUTICAL REPORT
GForce Life Sciences
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Curia | February 15, 2022
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced that Integrity Bio and LakePharma, two companies that it acquired last year, have fully transitioned to the Curia brand. This change reflects the accelerated organizational integration of the acquired companies into Curia and its provision of comprehensive biologics discovery, development and manufacturing solutions to customers. Curia completed the acquisition of Integrity Bio in August 2021...
Fiercepharma | June 08, 2020
Argenx is launching its first awareness efforts for autoimmune disease myasthenia gravis. The campaign began recently with a virtual conference, light-up nights around the country, a patient website debut and the promise of an upcoming documentary. The kickoff event on June 1, which was also the first day of MG Awareness Month, was a virtual meeting of physician and patient speakers along with the first MG Illuminate night that lit up the Zakim Bridge in Boston in the color teal. Throughout the ...
Businesswire | May 07, 2020
Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems has announced the completion of its recent engagement which examines the role of warehouse optimization in the pharma industry. This success story offers comprehensive insights into how Quantzig helped a pharma company who was facing a multitude of warehouse optimization and distribution challenges that were further complicated by the nature of the drugs that the...
AIkido Pharma Inc. | March 15, 2022
AIkido Pharma Inc. announced that the Company and Cedars-Sinai Medical Center have agreed under their Master Collaboration Agreement to co-fund and codevelop a novel immuno-oncology treatment designed to promote the destruction of cancer cells by a patient's own "killer" T-cells.
The Company and Cedars-Sinai will share costs, expenses and management of the drug co-development and will leverage the talent of Cedars-Sinai Technology Ventures and the lead scientists who...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE